HomeComparePET vs JNJ

PET vs JNJ: Dividend Comparison 2026

PET yields 4264.39% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PET wins by $13311240675884.30M in total portfolio value
10 years
PET
PET
● Live price
4264.39%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$13311240675884.33M
Annual income
$12,724,273,753,464,259,000.00
Full PET calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — PET vs JNJ

📍 PET pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPETJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PET + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PET pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PET
Annual income on $10K today (after 15% tax)
$362,473.35/yr
After 10yr DRIP, annual income (after tax)
$10,815,632,690,444,620,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, PET beats the other by $10,815,632,690,444,616,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PET + JNJ for your $10,000?

PET: 50%JNJ: 50%
100% JNJ50/50100% PET
Portfolio after 10yr
$6655620337942.18M
Annual income
$6,362,136,876,732,131,000.00/yr
Blended yield
95.59%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

PET
Analyst Ratings
7
Buy
Consensus: Buy
Price Target
$2.67
+5593.0% upside vs current
Range: $0.50 — $4.00
Altman Z
-11.7
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PET buys
0
JNJ buys
0
No recent congressional trades found for PET or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPETJNJ
Forward yield4264.39%2.14%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$13311240675884.33M$30.5K
Annual income after 10y$12,724,273,753,464,259,000.00$4,749.88
Total dividends collected$13271302165952.95M$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$2.67$228.73

Year-by-year: PET vs JNJ ($10,000, DRIP)

YearPET PortfolioPET Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$437,139$426,439.23$10,594$274.49+$426.5KPET
2$17,889,544$17,421,805.49$11,294$360.69+$17.88MPET
3$685,471,065$666,329,252.39$12,133$476.91+$685.46MPET
4$24,594,800,522$23,861,346,482.18$13,156$635.42+$24594.79MPET
5$826,455,266,378$800,138,829,819.73$14,432$854.61+$826455.25MPET
6$26,012,289,347,774$25,127,982,212,749.59$16,056$1,162.76+$26012289.33MPET
7$766,983,969,668,400$739,150,820,066,281.60$18,175$1,604.53+$766983969.65MPET
8$21,189,076,648,850,730$20,368,403,801,305,540.00$21,009$2,252.68+$21189076648.83MPET
9$548,567,217,215,019,650$525,894,905,200,749,440.00$24,911$3,229.73+$548567217214.99MPET
10$13,311,240,675,884,329,000$12,724,273,753,464,259,000.00$30,458$4,749.88+$13311240675884.30MPET

PET vs JNJ: Complete Analysis 2026

PETStock

Wag! Group Co. develops and supports a proprietary marketplace technology platform available as a website and mobile app that enables independent pet caregivers to connect with pet parents. Its platform allows pet parents, who require specific pet care services, such as dog walking, pet sitting and boarding, advice from licensed pet experts, home visits, training, and access to other services. The company was founded in 2015 and is based in Purchase, New York.

Full PET Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this PET vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PET vs SCHDPET vs JEPIPET vs OPET vs KOPET vs MAINPET vs ABBVPET vs MRKPET vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.